`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
` NDA 022272/S-017
`
`
`
`
`
`
`
`
`
`
`Food and Drug Administration
`Silver Spring MD 20993
`
`
`SUPPLEMENT APPROVAL
`
`
`Purdue Pharma, L.P.
`One Stamford Forum
`
`Stamford, CT 06901-3431
`
`
`Attention: Beth Connelly
`Associate Director, Regulatory Affairs
`
`
`
`Dear Ms. Connelly:
`
`Please refer to your Supplemental New Drug Application (sNDA) dated October 16, 2012,
`received October 19, 2012, submitted under section 505(b) of the Federal Food, Drug, and
`Cosmetic Act (FDCA) for OXYCONTIN (oxycodone hydrochloride controlled-release) Tablets.
`
`We acknowledge receipt of your amendments dated December 13, 2012, and March 29, 2013.
`
`This supplemental new drug application proposes modifications to the approved risk evaluation
`and mitigation strategy (REMS) for OXYCONTIN.
`
`We have completed our review of this supplemental application, as amended. It is approved,
`effective on the date of this letter.
`
`RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS
`
`
`The REMS for OXYCONTIN was originally approved on April 5, 2010, and modified on July 9,
`2012. The REMS consists of a Medication Guide, elements to assure safe use, and a timetable
`for submission of assessments of the REMS. Your proposed modifications to the REMS consist
`of:
`
`
`
` Revisions to Section VI. Specific Drug information for ER/LA Opioid Analgesic
`Products of the FDA Blueprint
`
` Revisions to the REMS Website, including the landing page and the webpage listing
`
`covered products under the REMS program
`
`
` Revisions to individual product Medication Guides for relevant drugs
`
`
` Revision to the REMS document to remove ANDA holders from the Timetable for
`Submission of Assessments
`
`Reference ID: 3292642
`
`

`

`
`
` NDA 022272/S-017
`Page 2
`
`
`Your proposed modified REMS, submitted on March 29, 2013, and appended to this letter, is
`approved.
`
`The timetable for submission of assessments of the REMS will remain the same as that approved
`on July 9, 2012. There are no changes to the REMS assessment plan described in our July 9,
`2012 letter.
`
`This REMS uses a single, shared system for the elements to assure safe use and the REMS
`assessments. This single, shared system, known as the ER/LA Opioid Analgesic REMS
`Program, currently includes the products listed in Appendix 1. Other products may be added in
`the future if additional NDAs or ANDAs are approved.
`
`We remind you that section 505-1(f)(8) of FDCA prohibits holders of an approved covered
`application with elements to assure safe use from using any element to block or delay approval
`of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could
`result in enforcement action.
`
`
`The requirements for assessments of an approved REMS under section 505-1(g)(3) include with
`respect to each goal included in the strategy, an assessment of the extent to which the approved
`strategy, including each element of the strategy, is meeting the goal or whether one or more such
`goals or such elements should be modified.
`
`In addition to the assessments submitted according to the timetable included in the approved
`REMS, you may propose a modification to the approved REMS when you submit a
`supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of
`the FDCA.
`
`If the assessment instruments and methodology for your REMS assessments are not included in
`the REMS supporting document, or if you propose changes to the submitted assessment
`instruments or methodology, you should update the REMS supporting document to include
`specific assessment instrument and methodology information at least 90 days before the
`assessments will be conducted. Updates to the REMS supporting document may be included in a
`new document that references previous REMS supporting document submission(s) for
`unchanged portions. Alternatively, updates may be made by modifying the complete previous
`REMS supporting document, with all changes marked and highlighted. Prominently identify the
`submission containing the assessment instruments and methodology with the following wording
`in bold capital letters at the top of the first page of the submission:
`
`
`NDA 022272 REMS CORRESPONDENCE
`
`(insert concise description of content in bold capital letters, e.g.,
`
`UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT
`
`METHODOLOGY)
`
`
`
`An authorized generic drug under this NDA must have an approved REMS prior to marketing.
`
`Should you decide to market, sell, or distribute an authorized generic drug under this NDA,
`contact us to discuss what will be required in the authorized generic drug REMS submission.
`
`Reference ID: 3292642
`
`

`

`
`
` NDA 022272/S-017
`Page 3
`
`
`Prominently identify the submission containing the REMS assessments or proposed
`modifications of the REMS with the following wording in bold capital letters at the top of the
`first page of the submission as appropriate:
`
`
`NDA 022272 REMS ASSESSMENT
`
`NEW SUPPLEMENT FOR NDA 022272
`
`PROPOSED REMS MODIFICATION
`
`
`NEW SUPPLEMENT (NEW INDICATION FOR USE)
`
`FOR NDA 022272
`REMS ASSESSMENT
`PROPOSED REMS MODIFICATION (if included)
`
`
`If you do not submit electronically, please send 5 copies of REMS-related submissions.
`
`REPORTING REQUIREMENTS
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`(21 CFR 314.80 and 314.81).
`
`If you have any questions, call Lisa E. Basham, Senior Regulatory Health Project Manager, at
`(301) 796-1175.
`
`
`Sincerely,
`
`{See appended electronic signature page}
`
`
`Judith A. Racoosin, M.D., M.P.H.
`Deputy Director for Safety
`Division of Anesthesia, Analgesia,
`and Addiction Products
`Office of Drug Evaluation II
`Center for Drug Evaluation and Research
`
`
`
`
`
`ENCLOSURE:
`REMS
`
`Reference ID: 3292642
`
`

`

`
`
`
`
`NDA 019813
`
`NDA 022321
`
`
`
` NDA 022272/S-017
`Page 4
`
`
` Appendix 1 List of applications
`
`NDA 021260
`AVINZA (morphine sulfate) extended-release capsules and its generic
`equivalent
`
`NDA 021306
`BUTRANS (buprenorphine) Transdermal System for transdermal
`administration
`
`NDA 006134
`DOLOPHINE (methadone hydrochloride) tablets and its generic equivalents
`
`ANDA 087997
`Methadone Oral Solution and its generic equivalents ANDA 087393
`Methadone Oral Solution and its generic equivalents ANDA 089897
`Methadone Oral Concentrate
`
` DURAGESIC (Fentanyl Transdermal System) for transdermal administration
`and its generic equivalents
`EMBEDA (morphine sulfate and naltrexone hydrochloride) extended- release
`capsules
`EXALGO (hydromorphone HCl) Extended-Release Tablets
`
`NDA 021217
`KADIAN (morphine sulfate) extended-release capsules and its generic
`
`NDA 020616
`equivalent
`MS CONTIN (morphine sulfate) controlled-release tablets and its generic
`equivalents
`NUCYNTA ER (tapentadol) extended-release oral tablets
`
`NDA 200533
`OPANA ER (oxymorphone hydrochloride) Extended-Release tablets
`
`NDA 201655
`OPANA ER (oxymorphone hydrochloride) Extended-Release tablets and its
`
`NDA 021610
`generic equivalents
`OXYCONTIN (oxycodone hydrochloride controlled-release) Tablets
`
`
`
`NDA 019516
`
`NDA 022272
`
`
`Reference ID: 3292642
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`JUDITH A RACOOSIN
`04/15/2013
`
`Reference ID: 3292642
`
`